Matthew Meyerson

Matthew Meyerson MD PhD is Professor of Pathology at Harvard Medical School, a Senior Physician at Dana-Farber Cancer Institute, and a Senior Associate Member of the Broad Institute. He is one of the architects of large-scale cancer genomics, having served as a co-leader of the Genome Data Analysis Center (GDAC) and analytical lead for multiple cancer types within The Cancer Genome Atlas (TCGA). His laboratory developed GISTIC, one of the most widely used algorithms for identifying significant somatic copy number alterations in cancer, and contributed SNP array and sequencing analysis pipelines foundational to TCGA and ICGC. Meyerson's group made the landmark discovery that FGFR1 amplification and NKX2-1 amplification drive distinct subtypes of squamous and adenocarcinoma of the lung, and characterized the genomic landscape of small-cell lung cancer. He also contributed to the discovery of ALK rearrangements in lung adenocarcinoma and the characterization of EML4-ALK fusions. His work on telomerase and cancer cell immortalisation contributed foundational understanding of cancer biology. Meyerson has received numerous honours including election to the National Academy of Medicine and the American Academy of Arts and Sciences.